PETS:NGS-PetMed Express Inc. (USD)

EQUITY | Pharmaceutical Retailers | Nasdaq Global Select

Last Closing

USD 4.15

Change

+0.10 (+2.47)%

Market Cap

USD 0.45B

Volume

0.27M

Analyst Target

USD 28.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PetMed Express Inc is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications and other health products for dogs, cats, and horses direct to the consumer.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc

-0.16 (-0.87%)

USD 14.83B
HITI High Tide Inc

-0.18 (-7.53%)

USD 0.18B
BIMI Bimi International Medical Inc

+0.11 (+9.57%)

USD 0.01B
MEDS Trxade Group Inc

+0.22 (+3.91%)

USD 8.10M
CJJD China Jo-Jo Drugstores Inc

+0.44 (+17.21%)

USD 5.41M
LFLY Leafly Holdings Inc

-0.09 (-4.50%)

USD 4.37M
LFLYW Leafly Holdings Inc

-0.01 (-28.87%)

N/A
MDVLQ MedAvail Holdings Inc

N/A

N/A

ETFs Containing PETS

BUY 0.00 % 0.95 %

N/A

N/A
WTD7:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

USD 0.06B
WTES:F WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

USD 0.06B
WTD7:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

+0.07 (+0.00%)

USD 0.06B
WTES:XETRA WisdomTree Europe SmallCa.. 0.00 % 0.00 %

+0.10 (+0.00%)

USD 0.06B
DFE:SW WisdomTree Europe SmallCa.. 0.00 % 0.00 %

+0.11 (+0.00%)

N/A
DFEA:SW WisdomTree Europe SmallCa.. 0.00 % 0.00 %

N/A

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.11% 25% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.11% 25% F 10% F
Trailing 12 Months  
Capital Gain -72.63% 25% F 11% F
Dividend Return 3.96% 50% F 60% D-
Total Return -68.67% 25% F 12% F
Trailing 5 Years  
Capital Gain -81.31% 75% C 15% F
Dividend Return 23.42% 100% F 86% B+
Total Return -57.88% 75% C 23% F
Average Annual (5 Year Horizon)  
Capital Gain -8.29% 100% F 29% F
Dividend Return -3.82% 100% F 33% F
Total Return 4.47% 100% F 84% B
Risk Return Profile  
Volatility (Standard Deviation) 48.78% 67% D+ 34% F
Risk Adjusted Return -7.83% 100% F 37% F
Market Capitalization 0.45B 75% C 38% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Pharmaceutical Retailers) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.50 80% 55%
Price/Book Ratio 0.87 63% 75%
Price / Cash Flow Ratio 3.57 38% 41%
Price/Free Cash Flow Ratio -9.28 88% 83%
Management Effectiveness  
Return on Equity -4.83% 88% 54%
Return on Invested Capital -2.09% 100% 51%
Return on Assets -2.64% 78% 45%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector